Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-26T05:38:51.776Z Has data issue: false hasContentIssue false

Radiologically isolated syndrome is antiquated amidst evolving McDonald criteria for multiple sclerosis

Published online by Cambridge University Press:  15 July 2019

Jagannadha Avasarala*
Affiliation:
Department of Neurology, University of Kentucky Medical Center & Kentucky Neuroscience Institute, 740 S Limestone, Lexington, KY 40536, USA
Fawad Yousuf
Affiliation:
Department of Neurology, University of Kentucky Medical Center & Kentucky Neuroscience Institute, 740 S Limestone, Lexington, KY 40536, USA
*
*Address correspondence to: Jagannadha Avasarala, MD, PhD, Department of Neurology, University of Kentucky Medical Center, Kentucky Neuroscience Institute, Lexington, KY, USA. (Email: [email protected])
Rights & Permissions [Opens in a new window]

Abstract

The diagnosis of radiologically isolated syndrome (RIS) is untenable in the modern era as new diagnostic criteria for multiple sclerosis (MS) continue to evolve. Even without optic nerve involvement, the shift in the diagnostic criteria for MS forces clinicians to make a diagnosis at the earliest possible time and appropriate treatment initiated. In this analysis, we revisit the original RIS criteria as published and conclude that RIS as a diagnostic entity is obsolete.

Type
Editorial
Copyright
© Cambridge University Press 2019

Based on a retrospective analysis of 44 patients, Okuda et al.Reference Okuda, Mowry and Beheshtian 1 coined the term radiologically isolated syndrome (RIS) to denote a cohort of patients who had incidental MRI of brain changes suggestive of multiple sclerosis (MS). Contrast enhancement, a hallmark of new lesion development in MS, was present in 21 brain and 7 cord lesions. Of the 44 patients studied, 24% had one or more gadolinium-enhancing lesions fulfilling the dissemination-of-time (DIT) diagnostic criteria for MS proposed in 2010;Reference Polman, Reingold and Banwell 2 additionally, cerebrospinal fluid (CSF) profiles were highly characteristic of MS in 27/44 (61.3%) fulfilling DIT criteria for MS based on the 2017 McDonald criteria.Reference Thompson, Banwell and Barkhof 3 The original studyReference Okuda, Mowry and Beheshtian 1 findings also included headaches, spells of uncertain etiology, lacunar syndrome, and hypersomnolence; such symptoms cannot be disregarded as atypical or ignored particularly in an era of evolving diagnostic criteria for MS.

In a follow-up study in 2011, Okuda et al.Reference Okuda, Mowry and Cree 4 noted that 25 of 71 patients (35.2%) had asymptomatic lesions in the cervical cord and 6/71 (8.4%) were gadolinium-enhancing. Eventually, 21/25 (84%) subsequently progressed to clinically isolated syndrome or primary progressive MS. It is noteworthy that none of the patients with asymptomatic cord lesions underwent a lumbar puncture to screen for MS, a procedure recommended by the 2017 McDonald criteriaReference Thompson, Banwell and Barkhof 3 in such instances. What would the classification be for patients with abnormal CSF findings and asymptomatic gadolinium-enhancing cord lesions? Is it possible to conclude a diagnosis of RIS without CSF studies in an era of new McDonald criteria?Reference Thompson, Banwell and Barkhof 3 Although Okuda et al.Reference Okuda, Mowry and Beheshtian 1 suggested that additional studies would define the risk of conversion to clinically definitive MS, the newer guidelines speed upReference Thompson, Banwell and Barkhof 3 MS diagnosis and make RIS criteria obsolete by adding CSF analyses as a biomarker of DIT. Most importantly, RIS patients have axonal loss, brain atrophy, and cognitive defects similar to changes that occur in MS,Reference Thompson, Banwell and Barkhof 3 , Reference Yamout and Al Khawajah 5 and while such patients have been described as asymptomatic, they are not clinically or pathologically silent. Taken together, RIS, first described as a diagnostic curiosity in 2009 and extended to include asymptomatic cord lesions in 2011, cannot continue in the current MS diagnostic developments. It is a diagnostic anachronism amidst continually evolving McDonald diagnostic criteria (Table 1).Reference McDonald, Compston and Edan 6 The new 2017 McDonald criteriaReference Thompson, Banwell and Barkhof 3 specify that symptomatic lesions seen on MRI of the brain fulfill the criteria of either DIT or dissemination in space (DIS) when lesions are noted in the supratentorial, infratentorial, or cord; the presence of cortical lesions alone can denote DIS, and CSF abnormalities are now linked to DIT criteria fulfilment.

TABLE 1. Differences between MS, RIS, and CIS

RIS = radiologically isolated syndrome; CIS = clinically isolated syndrome; MS = multiple sclerosis.

* First demyelinating event suggestive of MS.

** Can present with headaches, unexplained spells, or lacunar syndromes.

In a 2009 study by Okuda, patients who presented with migraine-type headaches, spells of uncertain etiology, or underwent imaging studies for “curiosity,” but were otherwise asymptomatic, were considered having RIS if their MRIs showed lesions suggestive of MS. However, evidence shows that patients who complain of headache as the first symptom no longer have inconsequential neurological symptoms;Reference Gebhardt, Kropp and Hoffmann 7 headache presentation might imply an inflammatory process that is even influenced by ethnicity.Reference Mohrke, Kropp and Zettl 8 , Reference Sahai-Srivastava, Wang and Ugurlu 9 A recent longitudinal study noted 78% of patients had headache as the first neurological symptom in MS.Reference Gebhardt, Kropp and Hoffmann 7 Incidentally, headache was the most common symptom presentation in the RIS study.Reference Okuda, Mowry and Beheshtian 1 Additionally, clinicians cannot dismiss “brain fog” or “episodic memory impairment” as not being consistent with MS presentation. Published data show that cognitive function in a cohort of 26 RIS patients, matched against healthy controls for age, gender, and level of education, was significantly lower in the RIS cohort,Reference Lebrun, Blanc and Brassat 10 indicating possible cortical involvement. Newer and higher-strength (4.7 T, 7 T, and 11 T) MRIs currently being studied threaten to confine RIS to a diagnostic curiosity as these have the potential to detect cortical lesions.

Lastly, MS does not have to present initially as a clinical attack – sometimes historical events and symptom evolution characteristic of MS provide reasonable evidence of a prior demyelinating event.Reference Polman, Reingold and Banwell 2

The struggle to diagnose patients with MS is real and challenging even to experts in the field. Adding to the myriad diagnostic issues, in more recent times, the exclusion of antibody-specific autoimmune diseases, specifically neuromyelitis optica spectrum disorders and anti-MOG-Ab disease (MOG-Ab-related optic neuritis, encephalitis, and myelitis – MONEM), is key to establishing a diagnosis of MS, among exclusion of other mimics. The McDonald criteria, originally developed in 2001,Reference McDonald, Compston and Edan 6 facilitate the diagnosis of MS in a variety of clinical presentations – without clear attacks and remissions and an insidious onset/presentation. Since disease onset can be insidious,Reference Polman, Reingold and Banwell 2 the application of newer clinical, radiological, and CSF criteria Reference Polman, Reingold and Banwell 2 , Reference Thompson, Banwell and Barkhof 3 to patients studied in the original studiesReference Okuda, Mowry and Beheshtian 1 , Reference Okuda, Mowry and Cree 4 would probably re-classify patients as having MS. Although diagnostic criteria mention clinical attacks as a prerequisiteReference Polman, Reingold and Banwell 2 for applying the radiological criteria and CSF analyses, not all patients present with a clinical attack.Reference McDonald, Compston and Edan 6

Incidental findings of white matter lesions that suggest MS appear in about 0.1–0.7% of the population as evidenced by autopsy and MRI studies,Reference Yamout and Al Khawajah 5 but it remains unknown if any of them fit the RIS criteria. It has been well documented that, even at the earliest stage of MS, loss of brain volume occurs as cortical and white matter atrophy accrue over time.Reference Bermel and Bakshi 11 Since axonal transection occurs early,Reference Trapp, Peterson and Ransohoff 12 treatment offers the best chance for function preservation. Failure to recognize RIS as MS could potentially lead to poor outcomes.

To cite a parallel example, patients with inflammatory bowel disease (IBD) can present with extra-intestinal signs that include the occurrence of white matter lesions in the brain that are asymptomatic or cause vague symptomatology.Reference Dolapcioglu, Guleryuzlu and Uygur-Bayramicli 13 The importance of finding brain lesions in IBD represents the recognition of extra-intestinal disease, leading to unearthing other systemic manifestations. Such novel findings and conclusions are likely only if we approach RIS from a similar perspective derived from an ever-evolving MS diagnosis. In a 2018 editorial,Reference Carroll 14 the statement suggesting the “need for further research into radiologically isolated syndrome and solitary sclerosis before they could be included in the criteria as MS” is questionable given that 24% of patients had gadolinium-enhanced lesions and 61.3% had CSF-positive data in the original RIS study.Reference Okuda, Mowry and Beheshtian 1 How does one include these in the RIS category using 2017 McDonald criteria?

To summarize, symptoms and examination findings coupled with brain/cord MRI data with typical lesions that are old and new (T1-gadolinium lesions) suggest MS while additional CSF studies when required can also aid in the diagnosis. Secondly, patients presenting with vague symptoms such as dizziness, vertigo, sensory symptoms, or “brain fog” should be investigated for MS as a possible diagnosis.

Disclosures

The authors do not have anything to disclose.

Competing interests

The authors report no competing interests.

Patient and public involvement

None.

References

References:

Okuda, DT, Mowry, EM, Beheshtian, A et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009; 72(9): 800805.CrossRefGoogle ScholarPubMed
Polman, CH, Reingold, SC, Banwell, B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2): 292302.CrossRefGoogle Scholar
Thompson, AJ, Banwell, BL, Barkhof, F et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162173.CrossRefGoogle ScholarPubMed
Okuda, DT, Mowry, EM, Cree, BA et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011; 76(8): 686692.CrossRefGoogle ScholarPubMed
Yamout, B, Al Khawajah, M. Radiologically isolated syndrome and multiple sclerosis. Mult Scler Relat Disord. 2017; 17: 234237.CrossRefGoogle ScholarPubMed
McDonald, WI, Compston, A, Edan, G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1): 121127.10.1002/ana.1032CrossRefGoogle ScholarPubMed
Gebhardt, M, Kropp, P, Hoffmann, F et al. Headache at the time of first symptom manifestation of multiple sclerosis: a prospective, longitudinal study. Eur Neurol. 2018; 80(3–4): 115120.CrossRefGoogle ScholarPubMed
Mohrke, J, Kropp, P, Zettl, UK. Headaches in multiple sclerosis patients might imply an inflammatorial process. PLoS One. 2013; 8(8): e69570.CrossRefGoogle ScholarPubMed
Sahai-Srivastava, S, Wang, SL, Ugurlu, C et al. Headaches in multiple sclerosis: cross-sectional study of a multiethnic population. Clin Neurol Neurosurg. 2016; 143: 7175.CrossRefGoogle ScholarPubMed
Lebrun, C, Blanc, F, Brassat, D et al. Cognitive function in radiologically isolated syndrome. Mult Scler. 2010; 16(8): 919925.CrossRefGoogle ScholarPubMed
Bermel, RA, Bakshi, R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006; 5(2): 158170.CrossRefGoogle ScholarPubMed
Trapp, BD, Peterson, J, Ransohoff, RM et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998; 338(5): 278285.CrossRefGoogle ScholarPubMed
Dolapcioglu, C, Guleryuzlu, Y, Uygur-Bayramicli, O et al. Asymptomatic brain lesions on cranial magnetic resonance imaging in inflammatory bowel disease. Gut and liver. 2013; 7(2): 169174.CrossRefGoogle ScholarPubMed
Carroll, WM. 2017 McDonald MS diagnostic criteria: evidence-based revisions. Mult Scler. 2018; 24(2): 9295.CrossRefGoogle Scholar
Figure 0

TABLE 1. Differences between MS, RIS, and CIS